Table 1.

Clinical and electrophysiological findings

		ATTRv (N = 35)	CIAP (N = 55)	p value
Clinical findings
TTR gene mutation	V30M P64L V122I	42,8% 51.4% 5.7%	-	-
Gender	Male Female	91.4% 8.6%	83.6% 16.4%	p = 0.289
Family history of neuropathy	No Yes	100% 0%	100% 0%	p = 0.569
Progressive neuropathy	No Yes	51.4% 48.6%	47.3% 52.7%	p = 0.701
Walking impairment	0 1 2 3	0% 48.6% 34.3% 17.1%	0% 69.1% 25.5% 5.4%	p = 0.083
Muscle weakness	No Yes	14.3% 85.7%	45.5% 54.5%	p = 0.002
Sensory symptoms	No Yes	2.8% 97.2%	9.1% 90.9%	p = 0.248
Carpal tunnel syndrome history	No Yes	42.9% 57.1%	76.4% 23.6%	p = 0.001
Autonomic symptoms	No Yes	68.6% 31.4%	72.7% 27.3%	p = 0.672
Age of onset (years)		64.3 ± 9.9	58.2 ± 11.2	p = 0.011
Disease duration (years)		4.3 ± 4.1	3.8 ± 2.7	p = 0.534
Electrophysiological findings
SAP median	Normal Reduced Absent	0% 25% 75%	40.8% 34.7% 24.5%	p < 0.001
SAP ulnar	Normal Reduced Absent	0% 45.5% 54.5%	31.6% 42.1% 26.3%	p < 0.001
SAP sural	Normal Reduced Absent	5.9% 26.5% 67.6%	6.4% 34% 59.6%	p = 0.671
SAP superficial	Normal Reduced Absent	5.6% 0% 94.4%	13.9% 13.9% 72.2%	p = 0.139
CMAP median	Normal Reduced Absent	14.3% 60.7% 25%	73.3% 24.5% 2.2%	p < 0.001
CMAP ulnar	Normal Reduced Absent	27.6% 68.9% 3.5%	73.5% 24.5% 2%	p < 0.001
CMAP tibial	Normal Reduced Absent	35.3% 17.6% 47.1%	20.8% 50% 29.2%	p = 0.011
CMAP peroneal	Normal Reduced Absent	17.9% 39.3% 42.8%	29.2% 35.4% 35.4%	p = 0.540

p values marked with bold indicate a statistically significant difference between the groups

SAP sensory action potential, CMAP compound motor action potential